BioCryst to Discontinue Internal Discovery Programs, Close Birmingham Facility by Year-End

MT Newswires Live06-29

BioCryst Pharmaceuticals (BCRX) said Monday it will discontinue its internal discovery programs and close its discovery center of excellence facility in Birmingham, Alabama, by the end of 2026 to prioritize external innovation and accelerate a rare disease pipeline.

The company said it made the decision after a strategic review and scientific diligence of its research capabilities, programs and priorities.

BioCryst said two clinical-stage programs that it will focus on advancing toward commercialization are navenibart for potential prophylaxis of hereditary angioedema, and BCX17725, an investigational KLK5 inhibitor for Netherton syndrome.

The company also said it has resolved a manufacturing delay and now expects Orladeyo oral pellets for patients 2 to under 12 years old to be available in early August.

BioCryst said it continues to expect full-year revenue of $635 million to $660 million, while analysts polled by FactSet expect $671 million. The company now expects full-year 2026 non-GAAP operating expenses of $420 million to $440 million, compared with prior guidance of $450 million to $470 million.

Shares of BioCryst were down more than 1% in pre-bell activity Monday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2647797873?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-29 20:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2647797873","market":"us","top_or_hot":-1,"title":"BioCryst to Discontinue Internal Discovery Programs, Close Birmingham Facility by Year-End","media":"MT Newswires Live","content":"<html><body><p> BioCryst Pharmaceuticals (BCRX) said Monday it will discontinue its internal discovery programs and close its discovery center of excellence facility in Birmingham, Alabama, by the end of 2026 to prioritize external innovation and accelerate a rare disease pipeline.</p><p>The company said it made the decision after a strategic review and scientific diligence of its research capabilities, programs and priorities.</p><p>BioCryst said two clinical-stage programs that it will focus on advancing toward commercialization are navenibart for potential prophylaxis of hereditary angioedema, and BCX17725, an investigational KLK5 inhibitor for Netherton syndrome.</p><p>The company also said it has resolved a manufacturing delay and now expects Orladeyo oral pellets for patients 2 to under 12 years old to be available in early August.</p><p>BioCryst said it continues to expect full-year revenue of $635 million to $660 million, while analysts polled by FactSet expect $671 million. The company now expects full-year 2026 non-GAAP operating expenses of $420 million to $440 million, compared with prior guidance of $450 million to $470 million.</p><p>Shares of BioCryst were down more than 1% in pre-bell activity Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioCryst to Discontinue Internal Discovery Programs, Close Birmingham Facility by Year-End</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioCryst to Discontinue Internal Discovery Programs, Close Birmingham Facility by Year-End\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-29 20:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> BioCryst Pharmaceuticals (BCRX) said Monday it will discontinue its internal discovery programs and close its discovery center of excellence facility in Birmingham, Alabama, by the end of 2026 to prioritize external innovation and accelerate a rare disease pipeline.</p><p>The company said it made the decision after a strategic review and scientific diligence of its research capabilities, programs and priorities.</p><p>BioCryst said two clinical-stage programs that it will focus on advancing toward commercialization are navenibart for potential prophylaxis of hereditary angioedema, and BCX17725, an investigational KLK5 inhibitor for Netherton syndrome.</p><p>The company also said it has resolved a manufacturing delay and now expects Orladeyo oral pellets for patients 2 to under 12 years old to be available in early August.</p><p>BioCryst said it continues to expect full-year revenue of $635 million to $660 million, while analysts polled by FactSet expect $671 million. The company now expects full-year 2026 non-GAAP operating expenses of $420 million to $440 million, compared with prior guidance of $450 million to $470 million.</p><p>Shares of BioCryst were down more than 1% in pre-bell activity Monday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BCRX","symbol_name":"BioCryst制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2647797873","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2647797873","pubTimestamp":1782734762,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"BioCryst Pharmaceuticals (BCRX) said Monday it will discontinue its internal discovery programs and close its discovery center of excellence facility in Birmingham, Alabama, by the end of 2026 to prio","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BCRX":"BioCryst制药","BK4139":"生物科技","BK4547":"WSB热门概念"},"translate_title":"BioCryst将停止内部发现计划，年底前关闭伯明翰工厂","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCRX":1},"content_text":"BioCryst Pharmaceuticals (BCRX) said Monday it will discontinue its internal discovery programs and close its discovery center of excellence facility in Birmingham, Alabama, by the end of 2026 to prioritize external innovation and accelerate a rare disease pipeline.The company said it made the decision after a strategic review and scientific diligence of its research capabilities, programs and priorities.BioCryst said two clinical-stage programs that it will focus on advancing toward commercialization are navenibart for potential prophylaxis of hereditary angioedema, and BCX17725, an investigational KLK5 inhibitor for Netherton syndrome.The company also said it has resolved a manufacturing delay and now expects Orladeyo oral pellets for patients 2 to under 12 years old to be available in early August.BioCryst said it continues to expect full-year revenue of $635 million to $660 million, while analysts polled by FactSet expect $671 million. The company now expects full-year 2026 non-GAAP operating expenses of $420 million to $440 million, compared with prior guidance of $450 million to $470 million.Shares of BioCryst were down more than 1% in pre-bell activity Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2647797873","isCrawlerRequest":true}